Roberto Iacovelli1, Elena Verri2, Maria Cossu Rocca2, Gaetano Aurilio2, Daniela Cullurà2, Ottavio De Cobelli3, Franco Nolè2. 1. Medical Oncology Division of Urogenital and Head & Neck Tumours, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy; Department of Radiology, Oncology and Human Pathology, "Sapienza" University of Rome, Viale Regina Elena 324, 00161 Rome, Italy. Electronic address: roberto.iacovelli@ieo.it. 2. Medical Oncology Division of Urogenital and Head & Neck Tumours, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. 3. Division of Urology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy.
Abstract
AIM: New hormonal agents are available for treating metastatic castration-resistant prostate cancer (mCRPC). We aim to define the incidence and relative risk (RR) of cardiovascular events in mCRPC patients treated with these agents. METHODS: Prospective studies were identified by searching the MEDLINE/PubMed, Cochrane Library and ASCO Meeting abstracts. Combined relative risks (RRs) and 95% confidence intervals (CIs) were calculated using fixed- or random-effects methods. RESULTS: We included six articles in this meta-analysis covering a total of 6735 patients who were used to evaluate cardiac toxicity. The use of new hormonal agents was associated with an increased risk of all grades of such toxicity (RR=1.32, 95% CI, 1.08-1.60; p=0.006) compared to a placebo, even if the absolute difference in terms of incidence was small at 14.8% versus 11.5%, respectively. No increased risk of grade 3-4 events (RR=1.35, 95% CI, 0.90-2.03; p=0.15) was observed. A total of 7830 patients were used to evaluate hypertension, and it was found that the use of new hormonal agents compared to a placebo was associated with an increased risk of all-grades (RR=1.84, 95% CI, 1.37-2.46; p<0.001) and grade 3-4 events (RR=1.77, 95% CI, 1.13-2.77; p=0.01). The absolute incidence was 12.5% versus 7.5% for all-grades and 3.7% versus 2.4% for grade 3-4. CONCLUSIONS: This analysis revealed a significant increase in the incidence and RR of cardiovascular toxicity in mCRPC treated with new hormonal agents as opposed to a placebo, even though the occurrence of all- and grade 3-4 events rose only 14% and 4%, respectively. Follow-ups for the onset of treatment-related cardiovascular events should therefore be considered in these patients.
AIM: New hormonal agents are available for treating metastatic castration-resistant prostate cancer (mCRPC). We aim to define the incidence and relative risk (RR) of cardiovascular events in mCRPC patients treated with these agents. METHODS: Prospective studies were identified by searching the MEDLINE/PubMed, Cochrane Library and ASCO Meeting abstracts. Combined relative risks (RRs) and 95% confidence intervals (CIs) were calculated using fixed- or random-effects methods. RESULTS: We included six articles in this meta-analysis covering a total of 6735 patients who were used to evaluate cardiac toxicity. The use of new hormonal agents was associated with an increased risk of all grades of such toxicity (RR=1.32, 95% CI, 1.08-1.60; p=0.006) compared to a placebo, even if the absolute difference in terms of incidence was small at 14.8% versus 11.5%, respectively. No increased risk of grade 3-4 events (RR=1.35, 95% CI, 0.90-2.03; p=0.15) was observed. A total of 7830 patients were used to evaluate hypertension, and it was found that the use of new hormonal agents compared to a placebo was associated with an increased risk of all-grades (RR=1.84, 95% CI, 1.37-2.46; p<0.001) and grade 3-4 events (RR=1.77, 95% CI, 1.13-2.77; p=0.01). The absolute incidence was 12.5% versus 7.5% for all-grades and 3.7% versus 2.4% for grade 3-4. CONCLUSIONS: This analysis revealed a significant increase in the incidence and RR of cardiovascular toxicity in mCRPC treated with new hormonal agents as opposed to a placebo, even though the occurrence of all- and grade 3-4 events rose only 14% and 4%, respectively. Follow-ups for the onset of treatment-related cardiovascular events should therefore be considered in these patients.
Authors: Giandomenico Roviello; Maria Rosa Cappelletti; Laura Zanotti; Angela Gobbi; Chiara Senti; Alberto Bottini; Andrea Ravelli; Alberto Bonetta; Giovanni Paganini; Daniele Generali Journal: Medicine (Baltimore) Date: 2016-10 Impact factor: 1.889
Authors: Sherry-Ann Brown; Svetlana Zaharova; Peter Mason; Jonathan Thompson; Bicky Thapa; David Ishizawar; Erin Wilkes; Gulrayz Ahmed; Jason Rubenstein; Joyce Sanchez; David Joyce; Balaraman Kalyanaraman; Michael Widlansky Journal: Front Cardiovasc Med Date: 2020-12-04
Authors: Marina T Van Leeuwen; Steven Luu; Howard Gurney; Martin R Brown; Sallie-Anne Pearson; Kate Webber; Lee Hunt; Soojung Hong; Geoffrey P Delaney; Claire M Vajdic Journal: JNCI Cancer Spectr Date: 2020-08-24
Authors: Raphael B Moreira; Marcio Debiasi; Edoardo Francini; Pier V Nuzzo; Guillermo De Velasco; Fernando C Maluf; Andre P Fay; Joaquim Bellmunt; Toni K Choueiri; Fabio A Schutz Journal: Oncotarget Date: 2017-08-08